Alizé Pharma launches Phase II clinical trial of AZP-531 in Prader-Willi syndrome

05-Mar-2015 - Alizé Pharma announced the launch of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi syndrome.The trial is a randomized, double blind and placebo controlled study. It aims to evaluate the safety and effects of a two-week treatment with AZP-531 ...

Scripps scientists develop test providing new pathway for identifying obesity, diabetes drugs

20-Sep-2010 - Scientists at The Scripps Research Institute have designed a new molecular test that will allow researchers to look for potential drugs targeting a human metabolic enzyme believed to stimulate the appetite and play a role in diabetes. The new test, which the scientists call a simple assay, will ...

Affymetrix Genotyping Arrays Identify Chromosomal Changes Not Detectable by Comparative Genomic Hybridization

Genetic studies on cancer and other developmental disorders presented at European Society of Human Genetics Meeting 2004 in Munich, Germany

17-Jun-2004 - Santa Clara. Affymetrix, Inc., announced that scientists at the European Society of Human Genetics Meeting 2004 (ESHG 2004) presented a series of studies using GeneChip® Mapping 10K Arrays to identify mutations in certain cancers and developmental disorders. These microarrays enable scientists to ...